Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Cancer immunotherapies, including immune checkpoint inhibitors and engineered T cells, are revolutionizing cancer treatment.
• While effective in many tumor types, these T cell-centered strategies only benefit a subset of patients, highlighting the need to overcome resistance mechanisms.

Purpose of the Study:

• To identify barriers limiting the trafficking of chimeric antigen receptor (CAR)-expressing T cells to solid tumors.
• To explore strategies for enhancing CAR T cell efficacy in combating solid tumors.

Main Methods:

• Review of accumulating evidence on obstacles hindering CAR T cell trafficking in solid tumors.
• Analysis of how the tumor microenvironment impedes CAR T cell homing, navigation, interaction, and persistence.

Main Results:

• Solid tumor microenvironments present multiple obstacles that hinder CAR T cell trafficking and function.
• These hurdles may partially explain the limited success of CAR T cell clinical trials in human carcinomas.

Conclusions:

• Understanding and overcoming barriers to CAR T cell trafficking is crucial for improving cancer immunotherapy.
• Modifying CAR T cells and the tumor environment offers significant opportunities to enhance anti-tumor activity and clinical applicability.